期刊文献+

间接药动-药效模型参数的计算程序 被引量:3

Program design of indirect pharmacokinetic and pharmacodynamic model
下载PDF
导出
摘要 目的:根据Dayneka等人提出的间接药动学-药效模型,设计一种计算机程序,用于估算间接药动学-药效模型的参数。方法:联合应用遗传算法和规划求解同时拟合给药后血药浓度-时间和效应-时间的数据,估算相应的药动学和药效学参数。结果:以口服一房室模型为例,对华法林的间接药动学和药效学结合模型的曲线进行拟合,算得PK参数tmax(3.40±1.52)h,cmax(56.39±6.85)μg/mL,t1/2(20.14±5.66)h;PD参数Kin(0.1009±0.0193)h-1,Kout(0.0938±0.0174)h-1,IC50(3.732±1.336)mg/L。结论:该程序可用于间接药动学-药效模型参数的求算,并同时描述药物的药动学和药效学行为特征。 Aim: A programme was designed to obtain the parameters of indirect pharmacokinetic-phannacedynamic model proposed by Dayneka. Methods: Using both genetic algorithm and planning solution, the parameters of the model can be estimated through simultaneous fitting of concentration-time data and response-time data. Results: Taking one compartment model following oral administration as example, the pharmacokinetic parameters value from curve fitting of the model of warfarin were: tmax(3.40 ± 1.52)h, cmax(56.39 ± 6.85) μg/mL, t1/2(20.14 ± 5.66)h; the pharmacodynamic parameters value were Kin(0. 100 9 ± 0.019 3)h^- 1, Kout(0.093 8 ± 0.017 4)h^ - 1, IC50(3.732 ± 1.336 ) mg/L. Conclusion: The application of the programme in obtaining parameters value of indirect pharmacokinetic-phannacedynamic model and characterization of the phannacokinetic/phannacedynamic behaviour of a drug had practical value in use.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2007年第1期55-59,共5页 Journal of China Pharmaceutical University
基金 国家高技术研究发展计划("八六三"计划)资助项目(No.2003AA2Z347A) 江苏省药物代谢动力学重点实验室资助项目(No.BM2001201)~~
关键词 间接药动学-药效学模型 华法林 遗传算法 规划求解 indirect phannacokinetic and phannacodynamic model warfarin genetic algorithm planning solution
  • 相关文献

参考文献14

  • 1Sheiner LB,Stanski DR,Vozeh S,et al.Simultaneous modeling of pharmacokinetics and pharmacodynamics:application to d-tubocurarine[J].Clin Pharmacol Ther,1979,25(3):358-371.
  • 2Holazo AA,Brazzell RK.Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentration and antiarrhythmic effect[J].J Clin Pharmacol,1986,26(5):336-345.
  • 3Derendorf H,Meibohm B.Modeling of pharmacokinetic/pharma-codynamic (PK/PD) relationships:concepts and perspectives[J].Pharm Res,1999,16(2):176-185.
  • 4Pérez-Urizar J,Granados-Soto V,Flores-Murrieta FJ,et al.Pharmacokinetic-Pharmacodynamic modeling:why?[J].Arch Med Res,2000,31(6):539-545.
  • 5黄晓晖,李俊.药动药效联合模型定量分析方法的研究现状[J].中国临床药理学与治疗学,2004,9(11):1205-1208. 被引量:5
  • 6Dayneka NL,Garg V,Jusko WJ.Comparison of four basic models of indirect pharmacodynamic responses[J].J Pharmacol Biopharm,1993,21(4):457-477.
  • 7Levy G,Mager DE,Cheung WK,et al.Comparative pharmaco-kinetics of coumarin anticoagulants L:Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man[J].J Pharm Sci,2003,92(5):985-994.
  • 8Zia-Amirhosseini P,Minthorn E,Benincosa LJ.Pharmacokinetics and pharmacodynamics of SB-240563,a humanized monoclonal antibody directed to human interleukin-5,in monkeys[J].J Pharmacol Exp Ther,1999,291(3):1 060-1 067.
  • 9Mariona J,Jose P.Pharmacokinetic/pharmacodynamic modelling of antipyretic and anti-inflammatory effects of naproxen in the rat[J].J Pharmacol Exp Ther,2001,297(1):198-205.
  • 10Lin SS,Chien YW.Pharmacokinetic-pharmacodynamic modeling of insulin:comparison of indirect pharmacodynamic response with effect-compartment link models[J].J Pharm Pharmacol,2002,54(6):791-800.

二级参考文献10

  • 1蒲俊 吉家锋.MATLAB6.0数学手册[M].上海:浦东出版社,2001.77-84.
  • 2[3]Meibohm B, Derendorf. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling[J]. Int J Clin Pharmacol Ther, 1997;35(10) :401 - 13
  • 3[5]NONMEN Project Group. NONMEN users guide, part 1 ~ 6 [M]. University of California: SanFrancisco, 1989
  • 4[6]Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models[J]. Clin Pharmacokinet, 1981;6(6):429
  • 5[7]Sun YN, DuBios DC, Almon RR, Pyszczyhski NA, Jusko WJ.Dose-dependence and repeated-dose studies for receptor / genemediated pharmacodynamic of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aninotransferase induction in rat liver[J]. J Pharmacokinet Biopharm, 1998; 26(6):619-48
  • 6[8]Katashima M, Yamada Y, Yamamoto K, Kotaki H, Sato H,Sawada Y. Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow[J]. J Pharmocokinet Biopharm, 1999;27(3) :283 - 96
  • 7Peter A. Meredith,Andrew W. Kelman,Henry L. Elliott,John L. Reid. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite[J] 1983,Journal of Pharmacokinetics and Biopharmaceutics(4):323~335
  • 8Wayne A. Colburn. Simultaneous pharmacokinetic and pharmacodynamic modeling[J] 1981,Journal of Pharmacokinetics and Biopharmaceutics(3):367~388
  • 9李海民,吴成柯.基于遗传算法的曲线段连接与拟合[J].西安电子科技大学学报,2000,27(1):44-48. 被引量:2
  • 10Law FCP,何绍雄.药代动力学药效学结合模型的应用进展[J].国外医学(药学分册),2001,28(1):1-5. 被引量:9

共引文献33

同被引文献67

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部